PD-089828 is an ATP competitive inhibitor of FGFR-1 , PDGFR-β and EGFR ( IC 50 s=0.15, 1.76, and 5.47 µM, respectively) and a noncompetitive inhibitor of c-Src tyrosine kinase ( IC 50 =0.18 µM). PD-089828 also inhibits MAPK with an IC 50 of 7.1 µM. PD-089828 inhibits PDGF-, EGF- and bFGF-mediated tyrosine kinase receptor autophosphorylation in vitro. PD-089828 has a long-lasting cellular activity.
Products | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Hepatitis Virus Infection | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > Pain | Products > Disease Areas > Hepatitis C Virus Infection | Products > Disease Areas > Obesity | Products > Disease Areas > Lung Fibrosis | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > JAK/STAT Signaling | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > FGFR | Products > Signaling Pathways > PDGFR | Products > Signaling Pathways > EGFR | Products > Signaling Pathways > Src
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.